A breakthrough! Huierkangxin exports to Macau for the first time - quadrivalent influenza virus subunit vaccine helps protect the health of the Macau region

Internationalization strategy takes a critical step

Recently, Huier Kangxin, a quadrivalent influenza virus subunit vaccine independently developed by Zhonghui Bio-B (02627), successfully arrived in the Macau Special Administrative Region and completed customs clearance, successfully achieved its first export, and officially entered the Macau market. This is not only an important sign that the company's scientific research strength and production quality have received international recognition, but also a key milestone in the company's promotion of a global layout.

The quadrivalent influenza virus subunit vaccine (HuierKangxin) was supplied to Macau this time. It uses advanced third-generation influenza vaccine technology and contains the main surface antigens of two influenza A and two influenza B viruses. It has characteristics such as high purity, good safety, and strong immunogenicity. Compared with traditional vaccines, this product has further optimized the process, significantly improved vaccination safety and protective effects, and is suitable for vaccination of various groups, including high-risk groups.

It is currently the influenza season, and the Macao Special Administrative Region continues to strengthen the prevention and control of respiratory infectious diseases. The timely introduction of this vaccine will provide Macao residents with high-quality and reliable immunization options and help strengthen local public health defenses.

The first dose ceremony was successfully held to work together to build a healthy Macau

On December 4, the first vaccination ceremony of the vaccine was successfully held at Macau Yinkui Hospital. The event conveyed the concept of “active health and active prevention” to all sectors in Macau, and also vividly explained our company's corporate vision of “let China use innovative global vaccines, and let the world use China's high-quality vaccines”.

In his speech, the head of the company's overseas business said, “We are very honored to be able to bring this advanced subunit influenza vaccine to our compatriots in Macau. This cooperation is not only a breakthrough in market expansion, but also an important step in realizing our vision for the world to use China's high-quality vaccines. We will continue to support public health in Macau and work together to protect the health of Macau residents”.

Continue to innovate and move towards a wider international stage

The vaccine was successfully delivered and used in Macau, which is a vivid reflection of the company's steady progress in its internationalization strategy. Up to now, the company has established cooperative relationships with many countries and regions. In the future, the company will continue to be driven by innovation, continuously improve the vaccine product pipeline, promote more high-quality products to serve the global market, and contribute China's strength to building a human health community.

This cooperation has accumulated valuable experience for the company to deepen its market layout and expand international channels in the Guangdong-Hong Kong-Macao Greater Bay Area. It has also provided China with a reliable solution for global influenza prevention and control.